At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TTNP Titan Pharmaceuticals
Market Closed 11-22 16:00:00 EST
3.71
-0.22
-5.60%
盘后3.71
+0.000.00%
18:13 EST
High3.93
Low3.57
Vol14.38K
Open3.57
D1 Closing3.93
Amplitude9.16%
Mkt Cap3.39M
Tradable Cap2.60M
Total Shares914.23K
T/O53.44K
T/O Rate2.05%
Tradable Shares700.06K
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Titan Pharmaceuticals- Appoints Brynner Chiam As Acting Principal Executive Officer & Acting Principal Financial Officer Of Co
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.